Iron oxide nanoparticles modulate lipopolysaccharide-induced inflammatory responses in primary human monocytes.
Co-stimulation of the immune system to more than one agent concomitantly is very common in real life, and considering the increasing use of engineered nanoparticles and nanomaterials, it is highly relevant to assess the ability of these materials to modulate key innate immune responses, which has not yet been studied in detail. We investigated the immunomodulatory effects of 10 nm and 30 nm iron oxide nanoparticles (IONPs) on primary human monocytes in the presence and absence of Toll-like receptor 4 agonist lipopolysaccharide (LPS). Prior to the cell studies, we characterized the physicochemical properties of the nanoparticles in cell culture medium and ensured that the nanoparticles were free from biological contamination. Cellular uptake of the IONPs in monocytes was assessed using transmission electron microscopy. Using enzyme-linked immunosorbent assay, we found that the IONPs per se did not induce the production of proinflammatory cytokines tumor necrosis factor-α, interleukin-6, and interleukin-1β. However, the IONPs had the ability to suppress LPS-induced nuclear factor kappa B activation and production of proinflammatory cytokines in primary human monocytes in an LPS and a particle dose-dependent manner. Using confocal microscopy and fluorescently labeled LPS, we showed that the effects correlated with impaired LPS internalization by monocytes in the presence of IONPs, which could be partly explained by LPS adsorption onto the nanoparticle surface. Additionally, the results from particle pretreatment experiments indicate that other cellular mechanisms might also play a role in the observed effects, which warrants further studies to elucidate the additional mechanisms underlying the capacity of IONPs to alter the reactivity of monocytes to LPS and to mount an appropriate cellular response.
Department of Cancer Research and Molecular Medicine.
Susann
S
Grosse
Department of Cancer Research and Molecular Medicine; Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway.
Jørgen
J
Stenvik
Department of Cancer Research and Molecular Medicine.
Asbjørn M
AM
Nilsen
D000327:Adsorption; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D005290:Ferric Compounds / Q000737:chemistry*; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007249:Inflammation / Q000235:genetics / Q000473:pathology*; D008070:Lipopolysaccharides / Q000494:pharmacology*; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D016328:NF-kappa B / Q000378:metabolism; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051197:Toll-Like Receptor 4 / Q000378:metabolism
D016207:Cytokines; D005290:Ferric Compounds; D008070:Lipopolysaccharides; D016328:NF-kappa B; D012333:RNA, Messenger; C495345:TLR4 protein, human; D051197:Toll-Like Receptor 4; C000499:ferric oxide
LPS adsorption; PBMCs; Toll-like receptors; cytokines; iron oxide nanoparticles; primary human monocytes
Nanomedicine (Lond). 2010 Oct;5(8):1261-75
21039201
Int J Nanomedicine. 2012;7:1387-97
22457596
Cell Death Differ. 2006 May;13(5):816-25
16410796
Toxicol Sci. 2007 Nov;100(1):303-15
17709331
Nanomedicine (Lond). 2008 Oct;3(5):627-35
18834270
J Biomed Mater Res. 1996 Jun;31(2):251-6
8731214
Nanotoxicology. 2013 May;7(3):235-50
22264124
Biomaterials. 2012 Feb;33(5):1477-88
22098780
Toxicol Lett. 2008 Jan 30;176(2):131-7
18079072
Atherosclerosis. 2007 Jul;193(1):102-11
16997307
Chin Med J (Engl). 2009 Aug 5;122(15):1821-5
19781333
Environ Health Perspect. 2007 Mar;115(3):403-9
17431490
Nanoscale. 2012 Nov 21;4(22):7135-42
23070238
Biochem Biophys Res Commun. 2013 Nov 29;441(4):737-42
24184477
Immune Netw. 2013 Jun;13(3):94-101
23885223
Nat Nanotechnol. 2007 Aug;2(8):469-78
18654343
Int J Biol Macromol. 2016 May;86:848-56
26854884
Toxicol Sci. 2009 May;109(1):113-23
19293371
Endocrinology. 2010 Feb;151(2):458-65
20016026
J Occup Med Toxicol. 2007 Dec 01;2:16
18053152
Exp Lung Res. 2003 Apr-May;29(3):149-64
12637227
Acta Biomater. 2012 Dec;8(12):4295-303
22842032
Part Fibre Toxicol. 2007 Feb 27;4:2
17326846
Toxicol Lett. 2013 Aug 14;221(2):110-7
23769963
Toxicol Appl Pharmacol. 2005 Sep 1;207(2 Suppl):269-75
15993911
Trends Immunol. 2002 Aug;23(8):375-8
12133792
Part Fibre Toxicol. 2011 Feb 09;8(1):8
21306632
ACS Nano. 2013 Aug 27;7(8):6997-7010
23808590
Toxicology. 2007 Sep 5;238(2-3):99-110
17614186
Biomaterials. 2007 Jun;28(16):2572-81
17320946
Inhal Toxicol. 2009 Jul;21 Suppl 1:115-22
19558243
PLoS One. 2012;7(1):e30899
22292072
Nitric Oxide. 2010 Nov 1;23(3):214-9
20547236
Nanomedicine (Lond). 2016 Feb;11(3):269-87
26787429
J Toxicol Environ Health A. 2014;77(4):177-91
24555677
Toxicol Lett. 2013 Feb 27;217(2):91-101
23266719
Small. 2005 May;1(5):482-501
17193474
Part Fibre Toxicol. 2012 Nov 09;9:41
23140310
J Immunol. 2004 Jul 15;173(2):1166-70
15240706
Br J Pharmacol. 2014 Sep;171(17):3988-4000
24724793
ScientificWorldJournal. 2011 Feb 14;11:382-90
21336454
Toxicology. 2009 Jun 16;260(1-3):142-9
19464580